MeSH term
Frequency | Condition_Probility | Complement 4a/*genetics | 34 | 97.0 |
Complement 4b/*genetics | 26 | 76.0 |
*Gene Conversion | 4 | 12.0 |
Haplotypes | 67 | 3.0 |
Humans | 444 | 0.0 |
Introns | 3 | 0.0 |
Major Histocompatibility Complex | 19 | 7.0 |
Research Support, Non-U.S. Gov't | 301 | 0.0 |
Adolescent | 62 | 0.0 |
Adult | 102 | 0.0 |
Aged | 49 | 0.0 |
Aged, 80 and over | 13 | 0.0 |
Antibody Specificity | 5 | 0.0 |
Case-Control Studies | 8 | 0.0 |
Complement 4/*immunology | 5 | 26.0 |
Complement Pathway, Classical | 5 | 4.0 |
Electrophoresis, Agar Gel | 10 | 1.0 |
Enzyme-Linked Immunosorbent Assay/methods | 2 | 0.0 |
Female | 178 | 0.0 |
Immunoenzyme Techniques | 4 | 0.0 |
Male | 175 | 0.0 |
Middle Aged | 74 | 0.0 |
Alleles | 118 | 1.0 |
Complement 3/*genetics | 6 | 10.0 |
*Genetic Predisposition to Disease | 5 | 0.0 |
Genotype | 40 | 0.0 |
HLA-B Antigens/*genetics | 4 | 1.0 |
Phenotype | 71 | 0.0 |
Blotting, Southern | 15 | 0.0 |
Chromosomes, Human, Pair 6/*genetics | 2 | 1.0 |
Complement 4a/genetics | 16 | 84.0 |
Complement 4b/genetics | 17 | 80.0 |
Hungary | 2 | 3.0 |
Iceland | 3 | 7.0 |
Research Support, U.S. Gov't, P.H.S. | 115 | 0.0 |
Sex Factors | 7 | 0.0 |
Tumor Necrosis Factor-alpha/genetics | 5 | 2.0 |
English Abstract | 13 | 0.0 |
Gene Expression | 5 | 0.0 |
Gene Frequency | 67 | 1.0 |
Genetic Markers | 20 | 0.0 |
HLA Antigens/*genetics | 45 | 5.0 |
Polymorphism, Genetic/*genetics | 4 | 0.0 |
Amino Acid Sequence | 30 | 0.0 |
Animals | 46 | 0.0 |
Autoimmune Diseases/genetics | 3 | 11.0 |
Complement/genetics | 11 | 40.0 |
Complement 4/*genetics | 86 | 62.0 |
*Major Histocompatibility Complex | 44 | 14.0 |
Molecular Sequence Data | 52 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Terminology | 4 | 2.0 |
Variation (Genetics) | 13 | 0.0 |
Lupus Erythematosus, Systemic/*genetics | 12 | 20.0 |
Polymorphism, Genetic | 54 | 1.0 |
Child | 54 | 0.0 |
Child, Preschool | 22 | 0.0 |
Complement 4a/*deficiency | 4 | 100.0 |
Complement 4b/*deficiency | 3 | 42.0 |
Genetic Predisposition to Disease | 8 | 0.0 |
Infant | 17 | 0.0 |
Base Sequence | 45 | 0.0 |
Comparative Study | 62 | 0.0 |
DNA/genetics | 12 | 0.0 |
Mice | 17 | 0.0 |
Molecular Structure | 2 | 0.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
Species Specificity | 6 | 0.0 |
*Alleles | 31 | 2.0 |
DNA/analysis | 9 | 1.0 |
DNA Primers | 3 | 0.0 |
Polymerase Chain Reaction/*methods | 4 | 0.0 |
*Polymorphism, Genetic | 33 | 0.0 |
Complement 4a/*analysis | 2 | 100.0 |
HLA-DQ Antigens/*blood | 2 | 33.0 |
Immunoglobulin Allotypes | 3 | 37.0 |
Reference Values | 12 | 0.0 |
Gene Expression Regulation | 4 | 0.0 |
Interferon Type II/pharmacology | 2 | 0.0 |
L Cells (Cell Line) | 2 | 0.0 |
Retroviridae Infections/genetics | 2 | 66.0 |
Chromosome Mapping | 32 | 0.0 |
Complement/*genetics | 22 | 37.0 |
Complement Activation/genetics | 2 | 25.0 |
Genes, Structural | 13 | 1.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
Complement 4a/deficiency/*genetics | 4 | 100.0 |
HLA-A Antigens | 5 | 1.0 |
Lupus Erythematosus, Systemic/complications/*genetics/immunology | 2 | 100.0 |
*Mutation | 3 | 0.0 |
Polymerase Chain Reaction | 14 | 0.0 |
Polymorphism, Restriction Fragment Length | 43 | 1.0 |
Antibodies/blood/*immunology | 2 | 20.0 |
Follow-Up Studies | 4 | 0.0 |
Logistic Models | 5 | 0.0 |
Treatment Failure | 2 | 0.0 |
Complement 2/genetics | 14 | 28.0 |
Gene Deletion | 16 | 0.0 |
HLA-DR Antigens/genetics | 21 | 5.0 |
Exons | 6 | 0.0 |
HLA-DQ Antigens/genetics | 6 | 2.0 |
Hepatitis B Vaccines/*immunology | 2 | 15.0 |
HLA-B8 Antigen/genetics | 2 | 11.0 |
HLA-DR3 Antigen/genetics | 2 | 8.0 |
*Haplotypes | 20 | 8.0 |
Major Histocompatibility Complex/*genetics | 14 | 8.0 |
Pedigree | 59 | 0.0 |
Autoimmune Diseases/genetics/immunology | 3 | 17.0 |
Endogenous Retroviruses/genetics | 2 | 40.0 |
HLA-A1 Antigen/*genetics | 2 | 28.0 |
HLA-B8 Antigen/*genetics | 3 | 25.0 |
HLA-DR3 Antigen/*genetics | 3 | 10.0 |
Haplotypes/genetics | 6 | 1.0 |
Steroid 21-Hydroxylase/genetics | 16 | 37.0 |
Blotting, Western | 5 | 0.0 |
Electrophoresis, Gel, Pulsed-Field | 2 | 0.0 |
Ethnic Groups/*genetics | 3 | 1.0 |
European Continental Ancestry Group/genetics | 10 | 1.0 |
Sampling Studies | 2 | 1.0 |
*Variation (Genetics) | 7 | 0.0 |
Adrenal Hyperplasia, Congenital/genetics | 3 | 27.0 |
European Continental Ancestry Group/*genetics | 7 | 2.0 |
Gene Conversion | 7 | 12.0 |
Gene Dosage | 3 | 0.0 |
Heterozygote | 15 | 0.0 |
Major Histocompatibility Complex/genetics | 4 | 7.0 |
Mutation | 7 | 0.0 |
Steroid 21-Hydroxylase/*genetics | 27 | 42.0 |
Tenascin/*genetics | 2 | 14.0 |
Family | 2 | 0.0 |
France | 3 | 1.0 |
*Linkage Disequilibrium | 2 | 1.0 |
Antigen-Antibody Complex/*blood | 4 | 7.0 |
Complement 4/deficiency/*genetics | 10 | 71.0 |
African Continental Ancestry Group/genetics | 4 | 1.0 |
Cohort Studies | 3 | 0.0 |
*Gene Deletion | 4 | 0.0 |
Homozygote | 16 | 0.0 |
Recurrence | 4 | 0.0 |
Binding, Competitive | 3 | 0.0 |
Cattle | 6 | 0.0 |
Complement 4a/*metabolism | 2 | 100.0 |
Complement 4b/*metabolism | 2 | 11.0 |
Serum Albumin, Bovine/immunology | 2 | 8.0 |
Blood Proteins/genetics/*immunology | 2 | 66.0 |
Complement 4/genetics/*metabolism | 2 | 50.0 |
Complement Hemolytic Activity Assay | 3 | 6.0 |
Disease Models, Animal | 3 | 0.0 |
Linkage (Genetics) | 41 | 1.0 |
*Eye Proteins | 2 | 1.0 |
Major Histocompatibility Complex/*genetics/immunology | 2 | 22.0 |
Proteins/genetics | 2 | 0.0 |
*Recombination, Genetic | 2 | 0.0 |
Tumor Cells, Cultured | 2 | 0.0 |
Complement 1 Inactivators/deficiency | 2 | 40.0 |
Complement 4b/metabolism | 3 | 12.0 |
*Complement Pathway, Classical | 2 | 2.0 |
Receptors, Complement/*metabolism | 2 | 1.0 |
Complement 4/analysis/*genetics | 6 | 75.0 |
Genetics, Population | 4 | 1.0 |
Incidence | 2 | 0.0 |
Risk Factors | 18 | 0.0 |
Survival Rate | 3 | 0.0 |
Genes, MHC Class II/*genetics | 3 | 4.0 |
Lymphotoxin/genetics | 2 | 3.0 |
Severity of Illness Index | 3 | 0.0 |
Cells, Cultured | 4 | 0.0 |
Restriction Mapping | 10 | 0.0 |
Sequence Analysis, DNA | 4 | 0.0 |
Immunogenetics | 3 | 6.0 |
Complement/deficiency/*genetics | 2 | 100.0 |
Molecular Biology | 2 | 0.0 |
*Multigene Family | 4 | 0.0 |
Cardiolipins/*immunology | 2 | 16.0 |
Immunoglobulin G/immunology | 2 | 0.0 |
Cell Line | 13 | 0.0 |
DNA/*genetics | 3 | 0.0 |
Peptide Fragments/*genetics | 2 | 4.0 |
Transfection | 4 | 0.0 |
Analysis of Variance | 2 | 0.0 |
*Homozygote | 4 | 2.0 |
*Phenotype | 2 | 0.0 |
Complement 2/*deficiency | 3 | 5.0 |
Haplotypes/*genetics | 3 | 1.0 |
Histocompatibility Antigens Class I/genetics | 4 | 4.0 |
Histocompatibility Antigens Class II/genetics | 17 | 14.0 |
*Genes, MHC Class II | 7 | 2.0 |
Adrenal Hyperplasia, Congenital/*genetics | 6 | 26.0 |
Complement 4/genetics | 28 | 45.0 |
Gene Rearrangement | 2 | 0.0 |
Point Mutation | 3 | 0.0 |
Spain | 3 | 0.0 |
Complement Factor B/*genetics | 20 | 15.0 |
Italy | 10 | 1.0 |
Pregnancy | 6 | 0.0 |
Genes, MHC Class II | 9 | 3.0 |
*Promoter Regions (Genetics) | 4 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
*Transcription, Genetic | 2 | 0.0 |
Complement 4/metabolism | 3 | 3.0 |
Serotyping | 2 | 0.0 |
*Biocompatible Materials | 3 | 8.0 |
In Vitro | 4 | 0.0 |
Histocompatibility Testing | 14 | 1.0 |
Japan | 4 | 0.0 |
Complement 3/analysis | 3 | 0.0 |
Lupus Erythematosus, Systemic/blood/*genetics | 2 | 33.0 |
*Cardiopulmonary Bypass | 3 | 3.0 |
Complement 3a/analysis | 2 | 11.0 |
Complement 4a/analysis | 3 | 42.0 |
Coronary Artery Bypass | 2 | 3.0 |
Complement Factor B/genetics | 22 | 31.0 |
*Linkage (Genetics) | 7 | 0.0 |
*Polymorphism, Restriction Fragment Length | 18 | 2.0 |
Protein Binding | 9 | 0.0 |
Radioligand Assay | 2 | 0.0 |
B-Lymphocytes/immunology | 3 | 0.0 |
Complement 4a/*biosynthesis | 3 | 100.0 |
Dogs | 2 | 0.0 |
Lymphocyte Activation | 3 | 0.0 |
Lymphocyte Culture Test, Mixed | 3 | 0.0 |
Swine | 3 | 0.0 |
Swine, Miniature | 2 | 5.0 |
Transplantation, Heterologous/*immunology | 2 | 3.0 |
Brazil | 3 | 1.0 |
*Gene Frequency | 4 | 0.0 |
Complement 4a/analysis/*genetics | 2 | 100.0 |
Complement Pathway, Classical/drug effects | 3 | 13.0 |
Sequence Alignment | 2 | 0.0 |
Antigen-Antibody Complex/metabolism | 5 | 9.0 |
Complement/*metabolism | 3 | 1.0 |
Precipitin Tests | 5 | 0.0 |
Epitopes | 5 | 0.0 |
India | 3 | 0.0 |
Chromosomes, Human, Pair 6 | 7 | 4.0 |
HLA-B Antigens/genetics | 10 | 4.0 |
Arthritis, Rheumatoid/immunology | 3 | 3.0 |
Autoimmune Diseases/*immunology | 2 | 1.0 |
Complement/*analysis/immunology | 2 | 22.0 |
Complement 4a/deficiency | 2 | 66.0 |
Disease Progression | 2 | 0.0 |
Lupus Erythematosus, Systemic/*immunology | 5 | 3.0 |
European Continental Ancestry Group | 14 | 2.0 |
Histocompatibility Antigens Class I/*analysis | 2 | 4.0 |
Histocompatibility Antigens Class II/*analysis | 3 | 2.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Complement 4b/analysis | 2 | 50.0 |
HLA-DQ Antigens/analysis | 3 | 6.0 |
HLA-DR Antigens/analysis | 4 | 0.0 |
Wales | 2 | 11.0 |
Haplotypes/*immunology | 3 | 12.0 |
Korea | 2 | 0.0 |
Biological Markers | 2 | 0.0 |
Complement 4/genetics/*immunology | 6 | 85.0 |
Enzyme-Linked Immunosorbent Assay | 6 | 0.0 |
Retrospective Studies | 3 | 0.0 |
Complement 4/*deficiency | 6 | 66.0 |
HLA-DR Antigens/*genetics | 8 | 1.0 |
South Africa | 2 | 1.0 |
Autoimmune Diseases/*genetics | 4 | 9.0 |
Lupus Erythematosus, Systemic/genetics | 2 | 16.0 |
Densitometry | 4 | 2.0 |
Diabetes Mellitus, Type 1/immunology | 2 | 11.0 |
Immunophenotyping | 3 | 0.0 |
Kidney Failure, Chronic/genetics/*immunology | 2 | 100.0 |
Diabetes Mellitus, Type 1/blood/*genetics | 2 | 50.0 |
Disease Susceptibility | 12 | 1.0 |
Blood Group Antigens/*genetics | 5 | 4.0 |
African Continental Ancestry Group/*genetics | 5 | 1.0 |
Deoxyribonucleases, Type II Site-Specific | 3 | 1.0 |
Complement 2/*analysis/genetics | 2 | 100.0 |
Complement 4/*analysis/genetics | 4 | 100.0 |
HLA Antigens/analysis | 10 | 4.0 |
Isoelectric Focusing | 3 | 0.0 |
DNA | 4 | 0.0 |
*Introns | 3 | 1.0 |
Protein Biosynthesis | 3 | 0.0 |
DNA Primers/chemistry | 3 | 0.0 |
*European Continental Ancestry Group | 3 | 3.0 |
*Genotype | 2 | 0.0 |
HLA Antigens | 3 | 2.0 |
Prospective Studies | 9 | 0.0 |
*Adrenal Hyperplasia, Congenital | 2 | 9.0 |
HLA-C Antigens/genetics | 2 | 2.0 |
Histocompatibility Antigens Class II/*genetics | 6 | 3.0 |
Cloning, Molecular | 9 | 0.0 |
Complement 4/chemistry/genetics/*metabolism | 2 | 100.0 |
Guinea Pigs | 6 | 0.0 |
Hydrogen-Ion Concentration | 3 | 0.0 |
Rats | 2 | 0.0 |
Recombinant Proteins/metabolism | 3 | 0.0 |
Sheep | 4 | 0.0 |
Sulfhydryl Compounds/metabolism | 2 | 5.0 |
Histocompatibility Antigens Class II/genetics/*immunology | 2 | 6.0 |
Infant, Newborn | 7 | 0.0 |
*Complement Activation | 6 | 1.0 |
Lupus Erythematosus, Systemic/*blood/*immunology | 2 | 25.0 |
Lupus Erythematosus, Systemic/*genetics/immunology | 11 | 23.0 |
Autoantibodies/genetics | 2 | 40.0 |
HLA-DQ Antigens/*analysis/genetics | 2 | 12.0 |
Complement Factor B/*immunology | 2 | 33.0 |
Electrophoresis, Polyacrylamide Gel | 13 | 0.0 |
Polymorphism, Single-Stranded Conformational | 2 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Complement 4/deficiency | 2 | 8.0 |
Complement Activation | 7 | 2.0 |
Multiple Sclerosis/*genetics/immunology | 2 | 11.0 |
Radioimmunoassay | 4 | 0.0 |
Complement 2/*deficiency/genetics | 2 | 7.0 |
Major Histocompatibility Complex/*immunology | 2 | 5.0 |
Binding Sites | 3 | 0.0 |
Complement 5/metabolism | 2 | 4.0 |
*Hemolysis | 2 | 2.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Blood Grouping and Crossmatching/*methods | 2 | 7.0 |
Chromatography, Ion Exchange | 3 | 0.0 |
Complement/analysis | 4 | 2.0 |
Complement 4/*deficiency/*genetics | 4 | 100.0 |
Chronic Disease | 2 | 0.0 |
Complement 2/deficiency | 3 | 13.0 |
Complement 3/genetics | 5 | 13.0 |
Diabetes Mellitus, Type 1/genetics/immunology | 2 | 16.0 |
Lupus Erythematosus, Systemic/genetics/immunology | 4 | 36.0 |
Receptors, Complement/genetics | 2 | 13.0 |
Antibodies, Monoclonal | 2 | 0.0 |
Complement/*analysis | 2 | 1.0 |
Time Factors | 3 | 0.0 |
*Exons | 2 | 0.0 |
Primates | 2 | 2.0 |
Sequence Homology, Nucleic Acid | 5 | 0.0 |
Family Health | 2 | 0.0 |
Chromosome Deletion | 22 | 3.0 |
HLA Antigens/genetics | 36 | 11.0 |
Complement 2/*genetics | 5 | 10.0 |
Gene Frequency/genetics | 3 | 0.0 |
Polymorphism, Genetic/genetics | 2 | 0.0 |
Sodium Dodecyl Sulfate | 2 | 3.0 |
Predictive Value of Tests | 2 | 0.0 |
Solubility | 4 | 0.0 |
Adrenal Hyperplasia, Congenital/enzymology/*genetics | 2 | 28.0 |
*Genes, MHC Class I | 4 | 1.0 |
Pseudogenes | 6 | 3.0 |
Genes, MHC Class I/*genetics | 2 | 2.0 |
Lupus Erythematosus, Systemic/ethnology/*genetics | 5 | 50.0 |
Complement 4a/*deficiency/genetics | 4 | 100.0 |
Chymotrypsin/pharmacology | 2 | 10.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Trypsin/pharmacology | 2 | 1.0 |
Complement 4a/metabolism | 3 | 60.0 |
Glycerol/metabolism | 3 | 7.0 |
Glycine/metabolism | 3 | 13.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Complement 4b/*deficiency/genetics | 2 | 50.0 |
HLA Antigens/classification | 2 | 28.0 |
*Adrenal Hyperplasia, Congenital/*genetics | 2 | 28.0 |
Multigene Family | 9 | 0.0 |
Electrophoresis | 4 | 1.0 |
Gene Amplification | 2 | 0.0 |
Immunologic Deficiency Syndromes/*genetics | 2 | 6.0 |
Perfusion | 2 | 0.0 |
Immunodiffusion | 2 | 0.0 |
Prognosis | 4 | 0.0 |
Immunoassay | 3 | 1.0 |
Complement 1s/metabolism | 2 | 16.0 |
Structure-Activity Relationship | 5 | 0.0 |
Complement/metabolism | 3 | 3.0 |
Ireland | 2 | 3.0 |
Oligonucleotide Probes | 3 | 0.0 |
Graves' Disease/*genetics/immunology | 2 | 18.0 |
Lymphotoxin/*genetics | 2 | 2.0 |
*Chromosome Deletion | 12 | 1.0 |
Asian Continental Ancestry Group | 3 | 1.0 |
*Chromosome Mapping | 5 | 0.0 |
Antibodies, Antinuclear/analysis | 3 | 4.0 |
Antigen-Antibody Complex/analysis | 2 | 1.0 |
Complement 4/analysis | 3 | 1.0 |
Complement 4b/physiology | 2 | 66.0 |
Dose-Response Relationship, Immunologic | 3 | 0.0 |
Complement 1/metabolism | 2 | 5.0 |
Complement Pathway, Classical/*genetics | 2 | 40.0 |
Hemolysis/genetics | 2 | 33.0 |
Plasmids | 4 | 0.0 |
DNA Probes | 6 | 0.0 |
Age Factors | 6 | 0.0 |
Tunisia | 2 | 4.0 |
Evolution | 5 | 1.0 |
Gorilla gorilla/*genetics | 2 | 25.0 |
Pongo pygmaeus/*genetics | 2 | 50.0 |
*Antibody Formation | 2 | 2.0 |
HLA Antigens/genetics/*immunology | 3 | 4.0 |
Haplotypes/genetics/*immunology | 2 | 100.0 |
Arthritis, Rheumatoid/genetics/*immunology | 3 | 8.0 |
Risk | 5 | 0.0 |
Abortion, Habitual/*genetics | 2 | 9.0 |
Penicillamine/*adverse effects/therapeutic use | 2 | 28.0 |
Pan troglodytes/*genetics | 2 | 7.0 |
Antibodies, Monoclonal/immunology | 3 | 0.0 |
Polymorphism, Genetic/immunology | 2 | 8.0 |
HLA-D Antigens/genetics | 4 | 10.0 |
Antigen-Antibody Complex/*immunology | 3 | 3.0 |
Hemolysis | 9 | 2.0 |
*Precipitin Tests | 2 | 28.0 |
Receptors, Complement/metabolism | 2 | 3.0 |
Antibodies/metabolism | 2 | 2.0 |
Complement 3 Convertase/metabolism | 2 | 5.0 |
Australia/epidemiology | 2 | 3.0 |
Complement 2/deficiency/genetics | 2 | 40.0 |
Complement 4/*deficiency/genetics | 11 | 68.0 |
Glomerulonephritis, IGA/genetics/*immunology | 4 | 50.0 |
Skin/pathology | 2 | 0.0 |
Complement 4/*analysis | 3 | 6.0 |
Erythrocytes/*immunology | 2 | 1.0 |
*Complement 4b | 4 | 12.0 |
HLA-D Antigens/*analysis | 3 | 4.0 |
DNA/*analysis | 2 | 0.0 |
HLA-D Antigens/*genetics | 5 | 3.0 |
Immunoblotting | 3 | 0.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Chi-Square Distribution | 2 | 0.0 |
Histocompatibility Antigens Class I/analysis | 2 | 2.0 |
Histocompatibility Antigens Class II/analysis | 4 | 2.0 |
*IgA Deficiency | 3 | 16.0 |
Disease Susceptibility/immunology | 2 | 2.0 |
*African Continental Ancestry Group | 5 | 4.0 |
United States | 5 | 0.0 |
Autoantibodies/analysis | 3 | 1.0 |
HLA Antigens/*analysis | 3 | 0.0 |
*Pseudogenes | 3 | 2.0 |
Nucleic Acid Hybridization | 11 | 0.0 |
Kinetics | 3 | 0.0 |
Lupus Erythematosus, Systemic/genetics/*immunology | 3 | 9.0 |
England | 2 | 1.0 |
African Continental Ancestry Group | 3 | 1.0 |
Complement 4/analysis/deficiency/*genetics | 2 | 66.0 |
Erythrocytes/immunology | 2 | 0.0 |
Rabbits | 3 | 0.0 |
Anaphylatoxins/metabolism | 2 | 66.0 |
Arthritis, Rheumatoid/*genetics/immunology | 2 | 4.0 |
Complement 4/*genetics/immunology | 9 | 75.0 |
Autoimmune Diseases/*genetics/immunology | 2 | 11.0 |
Finland | 3 | 1.0 |
Lactoylglutathione Lyase/genetics | 5 | 11.0 |
*Genes | 7 | 3.0 |
HLA Antigens/analysis/genetics | 5 | 19.0 |
Adrenal Hyperplasia, Congenital | 2 | 40.0 |
DNA/genetics/isolation & purification | 2 | 0.0 |
*Genes, Structural | 11 | 1.0 |
Steroid Hydroxylases/*genetics | 12 | 13.0 |
Diabetes Mellitus, Type 1/*genetics/immunology | 4 | 7.0 |
Complement 4a/*genetics/immunology | 2 | 100.0 |
Epitopes/genetics/immunology | 3 | 8.0 |
Complement 4/isolation & purification/*metabolism | 2 | 66.0 |
Diabetes Mellitus, Type 1/*genetics | 4 | 1.0 |
Antibodies, Monoclonal/diagnostic use | 4 | 0.0 |
Macromolecular Substances | 4 | 0.0 |
Epitopes/analysis | 2 | 0.0 |
Diabetes Mellitus, Type 1/genetics/*immunology | 4 | 8.0 |
Enzyme Precursors/*genetics | 10 | 9.0 |
Genes, MHC Class I | 4 | 3.0 |
Immunoglobulin A/genetics | 2 | 20.0 |
Anaphylatoxins/genetics | 2 | 100.0 |
Syndrome | 2 | 0.0 |
Complement Factor D/genetics | 2 | 100.0 |
Complement 4b | 39 | 41.0 |
Complement 4a | 45 | 76.0 |
HLA-B8 Antigen | 3 | 11.0 |
DNA Restriction Enzymes | 6 | 1.0 |
Arthritis, Rheumatoid/*genetics | 2 | 2.0 |
Biopsy | 2 | 0.0 |
HLA-A Antigens/genetics | 2 | 1.0 |
Crossing Over, Genetic | 2 | 2.0 |
Complement Fixation Tests | 2 | 2.0 |
HLA-DR Antigens/*analysis | 2 | 1.0 |
Steroid Hydroxylases/*deficiency | 2 | 7.0 |
Laboratory Techniques and Procedures | 2 | 6.0 |
Antigen-Antibody Complex | 2 | 1.0 |
Complement 4/*genetics/physiology | 2 | 100.0 |
*Bone Marrow Transplantation | 2 | 0.0 |
Psoriasis/*genetics | 2 | 3.0 |
HLA-DR4 Antigen | 4 | 6.0 |
Lupus Erythematosus, Systemic/chemically induced | 3 | 100.0 |
Epitopes/genetics | 2 | 2.0 |
HLA-DR3 Antigen | 9 | 23.0 |
Complement 4/deficiency/genetics | 2 | 40.0 |
Immunoglobulin Allotypes/genetics | 2 | 11.0 |
Genes | 2 | 0.0 |
Lactoylglutathione Lyase/*genetics | 2 | 4.0 |
Lyases/*genetics | 2 | 4.0 |
Chemistry | 5 | 2.0 |
Complement 4b/deficiency/genetics | 2 | 100.0 |
Isoantibodies/biosynthesis | 2 | 20.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Cyanogen Bromide | 2 | 3.0 |
Trypsin | 2 | 1.0 |
Japan/ethnology | 2 | 2.0 |
*HLA-B Antigens | 2 | 3.0 |
DNA, Recombinant/analysis | 2 | 10.0 |
Liver Neoplasms | 3 | 1.0 |
HLA-B Antigens | 10 | 2.0 |
Germany/ethnology | 2 | 15.0 |
Haploidy | 4 | 3.0 |
Multiple Sclerosis/genetics | 2 | 25.0 |
HLA-DR Antigens | 18 | 5.0 |
Antigen-Antibody Reactions | 2 | 0.0 |
Immunosorbent Techniques | 2 | 0.0 |
Acylation | 2 | 2.0 |
Molecular Weight | 6 | 0.0 |
Reagent Kits, Diagnostic | 2 | 1.0 |
HLA Antigens/*genetics/immunology | 2 | 4.0 |
*Chromosomes, Human, 6-12 and X | 4 | 2.0 |
Chromosomes, Human, 6-12 and X | 3 | 6.0 |
Peptide Fragments/isolation & purification | 2 | 3.0 |
Genes, Recessive | 2 | 0.0 |
Recombination, Genetic | 2 | 0.0 |
Epitopes/*genetics | 2 | 6.0 |
HLA-C Antigens | 2 | 1.0 |
Immunoelectrophoresis | 2 | 0.0 |
Hepatitis B Vaccines/*administration & dosage/immunology | 2 | 100.0 |
